Antimicrobial and immunomodulatory properties of PGLa-AM1, CPF-AM1, and magainin-AM1: Potent activity against oral pathogens

Regulatory Peptides

Volumn 194-195, Issue , 2014, Pages 63-68

  McLean, Denise T F ^a   McCrudden, Maelíosa T C ^a   Linden, Gerard J ^b   Irwin, Christopher R ^b   Conlon, J Michael ^c   Lundy, Fionnuala T ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Antimicrobial peptide; Cytokine; Host defence peptide; Lipopolysaccharide

Indexed keywords

GLYCYLISOLEUCYLLYSYLGLUTAMYLPHENYLALANYLALANYLHISTIDYLSERYLLEUCYLGLYCYLLYSYLPHENYLALANYLGLYCYLLYSYLALANYLPHENYLALANINYLVALYLGLYCYLGLYCYLISOLEUCYLLEUCYLASPARAGINYLGLUTAMINE; GLYCYLLEUCYLGLYCYLSERYLVALYLLEUCYLGLYCYLLYSYLALANYLLEUCYLLYSYLISOLEUCYLGLYCINE ALANYLASPARAGINYLLEUCYLLEUCINE AMINE; GLYCYLMETHIONYLALANYLSERYLLYSYLALANYLGLYCYLSERYLVALYLLEUCYLGLYCYLLYSYLVALYLALANYLLYSYLVALYLALANYLLLEUCYLLYSYLALANYLALANYLLEUCINE AMINE; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; AMPHIBIAN PROTEIN; ANTIMICROBIAL CATIONIC PEPTIDE; CPF-AM1 PEPTIDE, XENOPUS; MAGAININ DERIVATIVE; MAGAININ-AM1, XENOPUS; PGLA-AM1 PEPTIDE, XENOPUS AMIETI; XENOPUS PROTEIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CELL CULTURE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FIBROBLAST; FUSOBACTERIUM NUCLEATUM; HUMAN; HUMAN CELL; IMMUNOMODULATION; MINIMAL EFFECTIVE CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PORPHYROMONAS GINGIVALIS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS; XENOPUS LAEVIS; ANIMAL; BIOSYNTHESIS; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOUTH; SECRETION (PROCESS); SKIN; STREPTOCOCCUS MUTANS; STRUCTURE ACTIVITY RELATION; XENOPUS;

ANURA; CANDIDA ALBICANS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FUNGI; FUSOBACTERIUM NUCLEATUM; PIPIDAE; PORPHYROMONAS GINGIVALIS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS MUTANS; XENOPUS AMIETI;

AMPHIBIAN PROTEINS; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CANDIDA ALBICANS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FIBROBLASTS; FUSOBACTERIUM NUCLEATUM; INTERLEUKIN-8; MAGAININS; MICROBIAL SENSITIVITY TESTS; MOUTH; PORPHYROMONAS GINGIVALIS; PSEUDOMONAS AERUGINOSA; SKIN; STREPTOCOCCUS MUTANS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS; XENOPUS PROTEINS;

EID: 84921423477     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2014.11.002     Document Type: Article

References (27)

1. Conlon J.M. Structural diversity and species distribution of host-defense peptides in frog skin secretions. Cell Mol Life Sci 2011, 68:2303-2315.
2. Conlon J.M., Al-Ghaferi N., Ahmed E., Meetani M.A., Leprince J., Nielsen P.F. Orthologs of magainin, PGLa, procaerulein-derived, and proxenopsin-derived peptides from skin secretions of the octoploid frog Xenopus amieti (Pipidae). Peptides 2010, 31:989-994.
3. Conlon J.M., Sonnevend A., Pál T., Vila-Farrés X. Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group. Int J Antimicrob Agents 2012, 39:317-320.
4. Conlon J.M., Mechkarska M., Lukic M.L., Flatt P.R. Potential therapeutic applications of multifunctional host-defense peptides from frog skin as anti-cancer, anti-viral, immunomodulatory, and anti-diabetic agents. Peptides 2014, 57:67-77.
5. Lehrer R.I., Rosenman M., Harwig S.S.S.L., Jackson R., Eisenhauer P. Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods 1991, 137:167-173.
6. Steinberg D.A., Lehrer R.I. Designer assays for antimicrobial peptides. Disputing the "one-size-fits-all" theory. Methods Mol Biol 1997, 78:169-186.
7. Laboratory Clinical, Institute Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard M07-A8 2008, CLSI, Wayne PA.
8. Wiegand I., Hilpert K., Hancock R.E.W. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 2008, 32:163-175.
9. Felgentreff K., Beisswenger C., Griese M., Gulder T., Bringmann G., Bals R. The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides 2006, 27:3100-3106.
10. McLean D.T.F., Lundy F.T., Timson D.J. IQ-motif peptides as novel anti-microbial agents. Biochimie 2013, 95:875-880.
11. Killough S.A., Lundy F.T., Irwin C.R. Dental pulp fibroblasts express neuropeptide Y Y1 receptor but not neuropeptide Y. Int Endod J 2010, 43:835-842.
12. Hancock R.E.W. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001, 1:156-164.
13. Yin L.M., Edwards M.A., Li J., Yip C.M., Deber C.M. Roles of hydrophobicity and charge distribution of cationic antimicrobial peptides in peptide-membrane interactions. J Biol Chem 2012, 287:7738-7745.
14. Parisot J., Carey S., Breukink E., Chan W.C., Narbad A., Bonev B. Molecular mechanism of target recognition by subtilin, a class 1 lanthionine antibiotic. Antimicrob Agents Chemother 2008, 52:612-618.
15. Turnidge J.D., Bell J.M. Antimicrobial susceptibility on solid media. Antibiotics in laboratory medicine 2005, 8-59. Lippincott Williams & Wilkins, Philadelphia. 5th ed. V. Lorian (Ed.).
16. Bonev B., Hooper J., Parisot J. Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method. J Antimicrob Chemother 2008, 61:1295-1301.
17. Rosenfeld Y., Shai Y. Lipopolysaccharide (endotoxin)-host defense antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochim Biophys Acta 2006, 1758:1513-1522.
18. Vorland L.H., Ulvatne H., Rekdal O., Svendsen J.S. Initial binding sites of antimicrobial peptides in Staphylococcus aureus and Escherichia coli. Scand J Infect Dis 1999, 31:467-473.
19. Pier G.B. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. Int J Med Microbiol 2007, 297:277-295.
20. Kim S.-H., Jia W., Parreira V.R., Bishop R.E., Gyles C.L. Phosphoethanolamine substitution in the lipid A of Escherichia coli O157:H7 and its association with PmrC. Microbiology 2006, 152:657-666.
21. Schromm A.B., Brandenburg K., Loppnow H., Zahringer U., Rietschel E.T., Carroll S.F., et al. The charge of endotoxin molecules influences their conformation and IL-6-inducing capacity. J Immunol 1998, 161:5464-5471.
22. Coats S.R., To T.T., Jain S., Braham P.H., Darveau R.P. Porphyromonas gingivalis resistance to polymyxin B is determined by the lipid A 4'-phosphatase, PGN_0524. Int J Oral Sci 2009, 1:126-135.
23. Conlon J.M., Mechkarska M., Pantic J.M., Lukic M.L., Coquet L., Leprince J., et al. An immunomodulatory peptide related to frenatin 2 from skin secretions of the Tyrrhenian painted frog Discoglossus sardus (Alytidae). Peptides 2013, 40:65-71.
24. Ge Y., MacDonald D., Henry M.M., Hait H.I., Nelson K.A., Lipsky B.A., et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 1999, 35:45-53.
25. Hajishengallis G., Liang S., Payne M.A., Hashim A., Jotwani R., Eskan M.A., et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe 2011, 10:497-506.
26. Nair S.C., Anoop K.R. Intraperiodontal pocket: an ideal route for local antimicrobial drug delivery. J Adv Pharm Technol Res 2012, 3:9-15.
27. Van Dyke T., Paquette D., Grossi S., Braman V., Massaro J., D'Agostino R., et al. Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis: a phase-2 multi-center study. J Clin Periodontol 2002, 29:168-176.